A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Exclusion Criteria

• •Any disability that could have prevented the participants from completing all study requirements. -
• •Current medical or neurological condition that could have impacted cognition or performance on cognitive assessments.
• •Advanced, severe progressive or unstable disease that could have interfered with the safety, tolerability and study assessments, or put the participant at special risk.
• •History of malignancy of any organ system, treated or untreated, within the past 60 months.
• •Indication for, or current treatment with ChEIs and/or another AD treatment (e.g. memantine).
• •Contraindication or intolerance to MRI.
• •Brain MRI results showing findings unrelated to AD that, in the opinion of the Investigator might be a leading cause to future cognitive decline, could have posed a risk to the participant, or could have prevented a satisfactory MRI assessment for safety monitoring.
• •Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.
• •A positive drug screen at Screening, if, in the Investigator's opinion, was is due to drug abuse.
• •Significantly abnormal laboratory results at Screening, not as a result of a temporary condition.
• •Current clinically significant ECG findings.
• •Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism, vitiligo) or active / history of chronic urticaria in the past year.